Last reviewed · How we verify
Taxane plus Metronomic Capecitabine
Taxane inhibits microtubule dynamics, while metronomic capecitabine targets thymidylate synthase.
Taxane inhibits microtubule dynamics, while metronomic capecitabine targets thymidylate synthase. Used for Metastatic breast cancer, Metastatic non-small cell lung cancer.
At a glance
| Generic name | Taxane plus Metronomic Capecitabine |
|---|---|
| Sponsor | Sun Yat-sen University |
| Drug class | Taxane plus chemotherapy |
| Target | Microtubules, Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Taxanes, such as paclitaxel, work by stabilizing microtubules, thereby inhibiting cell division. Metronomic capecitabine, on the other hand, is a prodrug that is converted into 5-fluorouracil, which then inhibits thymidylate synthase, leading to DNA damage and cell death.
Approved indications
- Metastatic breast cancer
- Metastatic non-small cell lung cancer
Common side effects
- Neutropenia
- Fatigue
- Nausea
- Diarrhea
- Hand-foot syndrome
Key clinical trials
- The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). (PHASE4)
- MEtronomic TrEatment Option in Advanced bReast cAncer (PHASE2)
- Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer (PHASE2)
- Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer (PHASE3)
- Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC (PHASE3)
- Metronomic Therapy in Metastatic Breast Cancer. (PHASE3)
- MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer (PHASE2)
- Capecitabine With Digoxin for Metastatic Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Taxane plus Metronomic Capecitabine CI brief — competitive landscape report
- Taxane plus Metronomic Capecitabine updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI